The content on this site is intended for healthcare professionals only
Dr Rafael Sanchez-Salas talks to ecancer at the ASCO GU 2014 cancer congress.
Several indicators of intermittent androgen deprivation (IAD) outcomes in prostate cancer have been interpreted as potentially predictive, including prostate-specific antigen (PSA) nadir following first on-treatment period, off-phase interval duration and PSA doubling time. Improvement of the forecast of clinical outcomes is expected through identification and analysis of the different types of off-treatment period.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Looking at real world evidence on PSA testing in prostate cancer
Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC
Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC
OncoAlert Round Up for September 15-21, 2023
OncoAlert round up July 28th to August 3rd, 2023
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG
Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC
![Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )](https://cdn.ecancer.org/44737-m.jpg)
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery
